Ascentage Pharma Group International (HKSE:06855) Cash-to-Debt : 0.60 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ascentage Pharma Group International's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.60.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Ascentage Pharma Group International couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Ascentage Pharma Group International's Cash-to-Debt or its related term are showing as below:

HKSE:06855' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.6 Med: 5.29 Max: 544.84
Current: 0.6

During the past 8 years, Ascentage Pharma Group International's highest Cash to Debt Ratio was 544.84. The lowest was 0.60. And the median was 5.29.

HKSE:06855's Cash-to-Debt is ranked worse than
83.14% of 1524 companies
in the Biotechnology industry
Industry Median: 6.235 vs HKSE:06855: 0.60

Ascentage Pharma Group International Cash-to-Debt Historical Data

The historical data trend for Ascentage Pharma Group International's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ascentage Pharma Group International Cash-to-Debt Chart

Ascentage Pharma Group International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

8.66

1.93

1.57

0.82

0.60

Ascentage Pharma Group International Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial									1.57	1.09	0.82	0.94	0.60

Competitive Comparison of Ascentage Pharma Group International's Cash-to-Debt

For the Biotechnology subindustry, Ascentage Pharma Group International's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Cash-to-Debt falls into.

Ascentage Pharma Group International Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ascentage Pharma Group International's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1169.573	/	(674.21	+	1289.774)
	=	0.60

Ascentage Pharma Group International's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1169.573	/	(674.21	+	1289.774)
	=	0.60

Ascentage Pharma Group International (HKSE:06855) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ascentage Pharma Group International Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International (HKSE:06855) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ASPHF:USA

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company's geographical segments include the United States and Mainland China.

Executives

Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc	2301 Trustee
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Tian Yuan	2201 Interest of corporation controlled by you
Zhao Li	2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you

Ascentage Pharma Group International (HKSE:06855) Headlines

No Headlines